Objective: Patient involvement in treatment decisions is recommended in clinicianpatient encounters. Little is known about how oncologists engage patients in shared decision making in non-Western countries. We assessed the prevalence of shared decision making among Singaporean oncologists and analysed how they discussed prognosis.
| INTRODUC TI ON
In recent decades, the patient-physician relationship in Western countries has evolved from an asymmetrical interaction, in which patients are largely passive and physicians drive decisions, towards one where decision making is shared between patients and physicians. 1 The concept of shared decision making has since gained considerable clinical acceptance and is recognized as the gold standard for decision making. 2 Although current definitions vary, at its core shared decision making involves a process of making treatment decisions in a collaborative way between patients and physicians while exchanging information about different treatment options and with patients playing a major role in decisions. 2, 3 This transition to shared decision making has implications particularly in discussions related to treatment options of advanced cancer.
Patients with advanced cancer often need to make tough decisions between life-extending, burdensome and costly cancer-directed treatments, and care that focuses primarily on preserving quality of life. 4 When striving for patients to make informed decisions, patient-physician discussions should involve several key elements. Physicians should provide information about patient prognosis, discuss treatment options, address pros and cons of these options and discuss the uncertainty surrounding them. 5 Additionally, oncologists should elicit patient treatment preferences. When patients are involved in decision making, they have better outcomes, such as adherence with treatments, psychological well-being and satisfaction with their medical care. [6] [7] [8] Patient involvement in decision making now represents the gold standard in many Western countries. 1, 6 In most Asian countries, however, the patient-physician relationship is still largely paternalistic. Singapore (the setting of this study), a multicultural South-East Asian country with a developed economy, is currently undergoing the transition from a paternalistic to a shared decision-making model. 9 Studies show that many Singaporeans desire complete information regarding their illness and prefer to be involved in making treating decisions with their physician. 10, 11 As a result, there is a growing need for Singapore physicians to not just be technical experts but also to encourage patients and caregivers to be active participants in decision making. Within the context of advanced cancer consultations, physicians will also need to have an explicit discussion of prognosis without which patients may overestimate their prognosis and chance of cure and be unable to make truly informed decisions. [12] [13] [14] Further, in Singapore and in many other countries, family caregivers have greater power or control over patient's treatment decisions, particularly if the patient is older or less educated. 15 There is anecdotal information to suggest that such patients may be excluded from the decision-making process. However, currently there is sparse literature from Asian countries describing the extent of physician encouragement of patient participation in decision making, explicit prognostic discussions and involvement of caregiver only during consultations. Most studies rely on patient perceptions of their involvement in decision making and reports of their prognostic understanding, acknowledging that perceptions may be systematically biased by recall, low expectations of the patient themselves to be involved in decision making and their hope of a cure. 16, 17 Few have looked at actual encounters.
The aim of this study was to describe the prevalence of shared decision making among Singaporean oncologists and how oncologists discussed prognosis. Our long-term goal involves designing efforts to improve patient involvement in decision making in this Asian setting.
| ME THODS

| Sample
Between March 2015 and January 2016, the study team first approached medical oncologists from two large cancer centres in Singapore and obtained their written consent to participate in the study. These two centres see more than 70% of all cancer patients in Singapore. 18 
| Surveys
We placed a digital audio recorder unobtrusively in the consultation room to audio-record oncologist-patient consultations. We audio-recorded consultations rather than video recording or directly observing because audio recording is unobtrusive, less likely to modify naturally occurring behaviours during consultation, allows repeated reviewing of data for several behaviours and by multiple study team members and is less expensive. 19 Oncologists were not aware of the outcomes being assessed in the study. The consultations included both new cases and follow-up cases. Each patient/caregiver was recorded only once. We surveyed oncologists and collected data on their age, gender and clinical grade.
We also surveyed patients and caregivers pre-consultation about their demographics (age, gender, ethnicity, marital status and education).
| Analysis
This study involved applying a codebook (Appendix S1) to create quantitative counts for the elements of shared decision making. We translated (when necessary) and transcribed verbatim all audio recordings to allow a detailed study of consultations. Native language speakers checked transcriptions and translations extensively for quality. Two coders coded together all consultations.
We first identified the treatment decision being made during the consultation. We counted and recorded the number and type of treatment decisions being made in each consultation. These included starting or not starting a treatment, continuing or stopping treatment, starting another round of treatment immediately or after waiting for some time, and choosing between treatment options. Within the context of each treatment decision, we developed a coding system to assess three outcomes: (1) oncologist encouragement of patient participation in decision making, 
Decision Support Analysis Tool and Decision Analysis System for
Oncology), it was not derived from any one system in particular. 20 We chose not to use any of these existing tools as their validity has not been evaluated in our local setting. Some aspects of decision making unique to our local context such as oncologist involvement of only the caregiver in pertinent aspects of decision-making conversations (outcome 2) are not included in existing tools. Further, two of three existing tools have not specifically been developed for use with advanced cancer patients and thus do not include an assessment of prognosis discussions (outcome 3) which is essential to allow patients to make informed decisions regarding their treatment.
For the first outcome, we coded five oncologist behaviours signalling their encouragement of patient participation in treatment discussions. These included (a) oncologist checked patient perception or understanding of test results, treatment options and prognosis (either before or after disclosure), (b) oncologist listed more than one treatment option, (c) oncologist discussed pros and cons of each treatment option (at least one of each was discussed), (d) oncologist discussed treatment uncertainty with each option (letting the patient know that it is unclear whether the treatment will work) and (e) oncologist checked patient preference or deferred to patient preference. We coded each behaviour when it was present in the consultation. We scored each consultation based on the number of behaviours exhibited. Total score ranged from 1 to 5.
For the second outcome, we identified oncologist behaviours that may have affected patient participation in decision making by possibly excluding the patient from the conversation. This included two types of behaviours-(a) oncologist, when discussing treatment pertinent information, switched language from patient's primary language (eg Mandarin) to English and (b) oncologist discussed treatment pertinent information with only the caregiver after the caregiver asked the patient to step out of the consultation room. We scored each consultation as 0 or 1 based on the presence or absence of any of these two behaviours.
Lastly, we coded how prognostic information was communicated, for instance in either numerical terms (eg as 'life expectancy' and 'median survival'); or semi-quantitative terms (eg 'a few more weeks/months', 'months not years'); or qualitative terms (eg 'not much time left', only saying that 'the condition was incurable' without giving any specific information on survival, or just saying that 'the disease was advanced' or 'looked bad' but not giving any further information). We coded each instance of prognostic discussion as 0 (=no prognosis disclosed), 1 (=qualitative prognosis) or 2 (=numerical or semi-quantitative prognosis). We then scored each consultation based on the highest code assigned within that consultation.
We used a Poisson regression model predicting the number of oncologist behaviours signalling their encouragement of patient participation in treatment discussions. To assess whether oncologist behaviours varied by key patient and oncologist characteristics, we included as independent variables patient age, gender, marital status and education as well as oncologist age, gender, clinical grade and country of basic medical training and consultation length.
We used chi-squared test to assess the association of oncologist involvement of caregiver only with patient (age, gender, education, ethnicity and marital status), caregiver (age, gender, education, ethnicity and marital status) and oncologist characteristics (age, gender and clinical grade).
Finally, using an ordered logistic regression model, we assessed the association between oncologist disclosure of a more explicit prognosis (0 = no prognosis disclosed, 1 = qualitative prognosis, 2 = numerical or semi-quantitative prognosis). Again, to test variation in oncologist disclosure of prognosis by important patient and oncologist characteristics, the following independent variables were included-patient age, gender, ethnicity, marital status, education and whether patient asked prognosis-related question, and oncologist age, gender, clinical grade and country of basic medical training.
We used NVivo for all coding and Stata for all analyses.
| RE SULTS
| Sample characteristics
We approached 43 oncologists to participate in the study, and 37 (86%) agreed. Of these, we audio-recorded consultations of 30 oncologists. Out of the 230 eligible patients approached, 113 (49%) patients and their primary informal caregivers consented to participate. A total of 100 out of 113 patients who consented (88%) completed a pre-consultation survey and had their consultations audio-recorded. Of these 100, 77 had a primary informal caregiver accompanying them who also consented and completed the surveys.
We excluded 59 consultations from analysis because they did not contain any decision making-19 did not involve any treatment married (86%). Caregivers were, on average, better educated than patients, with 31% having university education and above (Table 1) .
Twenty-five oncologists were involved in the 41 consultations analysed. They were, on average, 40 (SD = 7.9) years old, 72%
were male and 28% were senior residents/fellows (Table 1) . In all consultations, the oncologist spoke the same language as the patient and/or caregiver. Table 2 shows the extent to which oncologists showed each of the five behaviours encouraging patient participation in decision making. In most consultations, oncologists listed more than one treatment option (90%). They also checked patient's understanding (34%) and discussed pros and cons (34%), and uncertainty (29%) for all treatment options. Oncologists showed at least one of these behaviours in all consultations and all of these behaviours in only 2 (5%) consultations. On average, oncologists exhibited 2.7 (SD = 1.1) of these five behaviours in each consultation.
| Oncologist encouragement of patient participation in decision making
Oncologists showed more of these five behaviours when patients were older than 60 years old (β: 0.25; P = .02). The number of behaviours did not vary by other patient or oncologist characteristics (Table 3) . 
| Oncologist involvement of caregivers only in decision making
In 6 (15%) consultations, oncologists discussed pertinent information about the patient's treatment only with the caregiver in a way that may have excluded the patient from decision making. Of these consultations, in 4 (10%) consultations, they spoke to the patient in one language and in another language with the caregiver. When discussing vital information such as scan results and treatment options, they switched from the patient's preferred language to another language (eg from Mandarin to English). It was unclear whether the patient understood the language spoken to the caregiver. In 2 (5%) consultations, the oncologist discussed prognosis with only the caregiver after the patient was asked to leave the consultation room by the caregiver.
Oncologists were more likely to involve only the caregiver in consultations with patients older than 60 years (24% vs 0%, P < .05) and when patients were lower educated (25% vs 4%, P < .05). This behaviour did not vary significantly by any other patient, caregiver or oncologist characteristics.
| Oncologist disclosure of prognosis
Oncologists discussed prognosis in 21 (51%) consultations. They provided a more explicit prognosis to only 7 (17%) of the patients, which included a numerical prognosis to 6 (15%) patients and a semiquantitative prognosis to only 1 (2%) patient. They gave a qualitative prognosis to 14 (34%) of the patients which included telling 8 (20%) patients that their disease was incurable, 3 (7%) that it was advanced, 1 (2%) that it looked bad and 2 (5%) that they had been cured ( Table 2 ). Only in 8 (20%) consultation, patients/caregivers asked oncologist questions related to their prognosis. Table 3 shows that oncologists were more likely to provide a more explicit prognosis to patients older than 60 years (OR: 7.5; P < .05) and to those patients/caregivers who asked questions related to prognosis (OR: 50.6; P < .01). There was no variation in providing prognostic information by other patient and oncologist demographics.
TA B L E 2 Oncologist encouragement of patient participation in decision making, their likely involvement of only the caregiver and discussion of prognosis (n = 41) 
Codes
Number of encounters n (%) Illustrative quotes
Oncologist encouragement of patient participation in decision making
| D ISCUSS I ON
In a multi-ethnic Asian setting, we analysed consultations between oncologists and patients with stage IV cancer, most of whom were accompanied by their caregivers. First, we found that oncologists displayed some behaviours that encourage decision making. We also found that in some areas, their behaviours could have been more frequent. Second, there were instances in which the oncologists discussed pertinent information only with the caregiver in a way that may have excluded the patient from decision making; this behaviour was also more likely to occur with older patients. Third, they mostly disclosed prognosis less explicitly and were more likely to give an explicit prognosis when patients or caregivers asked questions related to their prognosis.
We found that as recommended, oncologists listed more than one treatment option in most consultations. Oncologists also did things to engage patients but to a lesser degree. For instance, they checked patient understanding and discussed both pros and cons and uncertainty related to all treatment options. They did this in about one-third of the encounters, which is impressive given that anecdotal information suggests that these oncologists have not received any extensive training in shared decision-making communication beyond a few lectures and role plays in medical school.
Providing information on both pros and cons may help patients to better weigh their treatment options to make an informed choice.
Our results corroborate previous findings from many countries that discussion of pros and cons may not always happen during consultations. [21] [22] [23] [24] [25] [26] Studies also suggest that even when such discussion happens, they may be incomplete. 27 Especially in the context of advanced cancer, treatment options often have uncertain benefits and decisions need to be made by weighing the pros and cons and the uncertainty related to each option. Such discussions are therefore an essential element of shared decision making.
Oncologists may benefit from a specialized communication training to conduct such discussions. 28, 29 A possible barrier to such discussions may be the short consultation time as also suggested by our study findings. Average consultation time for visits recorded in our study was 15 minutes compared to 23 minutes in the United States. 30 Oncologist involvement of only the caregiver in pertinent aspects of decision-making conversations, though relatively rare, continues to exist. In Singapore and in many other Asian countries, family care-
givers are known to have more power or control over patient's treatment decisions, particularly if the patient is older or less educated. 15 During decision making, family involvement has been seen as playing a key role as compared to the emphasis on patient autonomy in most Western countries. 15, 31, 32 Consistent with Confucian principles of decision making, family members feel the responsibility to make decisions for the patient. In this regard, oncologist can choose not to disclose diagnosis and/or prognosis to maintain patient's hope and in keeping with the best interest of the patient. 32, 33 However, as policy makers in Singapore 9 and many other countries call for a shared decision-making model, oncologists may need to ensure that all patients, especially those who are older, have the opportunity to participate in the decision-making process should the patient wishes to do so. They can elicit patient preferences for information and decision making, and respond to family concerns regarding conveying prognosis and other treatment-related information directly to patients. If patients prefer that their families be given information rather than them, then it should be ethically acceptable to do so.
It was encouraging that when patients and caregivers specifically asked questions about their prognosis, oncologists responded explicitly. Several studies have shown that patients want to be told about their prognosis in a sensitive but honest manner 34, 35 ; this has also been found in several Asian countries such as Taiwan, Japan, Nepal and Hong Kong. [36] [37] [38] [39] [40] Oncologists may, in general, withhold explicit prognostic information from patients due to fear of making patients emotionally overwhelmed. [41] [42] [43] [44] Younger patients less than 60 years have been seen to be more worried of cancer diagnosis and poor prognosis [45] [46] [47] [48] possibly making oncologists in our study less likely to disclose their prognosis. Explicit discussions about prognosis may be necessary for patients to make informed decisions. In the absence of explicit prognostic information, many patients report not knowing or misunderstanding the status of their disease and intent of treatment. 49 For instance, a systematic review reported that up to 75% of the patients are unaware of their poor prognosis. 50 A study from the United States found that 69% of patients with advanced lung cancer and 81% of patients with colorectal cancer did not believe that their chemotherapy was not curative though the odds for more inaccurate beliefs were higher among patients who rated their communication more favourably. 13 Training oncologists to convey prognosis by first asking permission from patients to do and then conveying that information in a sensitive manner as well as empowering patients to actively ask questions related to their prognosis may increase the frequency of explicit prognostic discussions during consultations.
The main limitation of this study is the small sample size and that a large number of consultations were excluded as they did not involve any treatment discussion. We were also unable to differentiate consultations based on whether these were new or follow-ups and based on length of relationship between oncologist and patient. Second, we do not know the extent to which patient wished to be involved in the decision-making process. Third, since this was a cross-sectional study design, we have no knowledge about additional information communicated to patients or on the oncologist behaviour during other visits with the same patients. Fourth, we are unable to comment on whether all relevant treatment options were presented and whether all possible pros and cons including significant side-effects were discussed in a balanced way during the consultation. We are also unable to distinguish to what extent oncologists' listing of treatment options gave patients the appearance of choice vs a substantive choice. Fifth, for the 4 consultations in which oncologist switched from patient's preferred language to another language while discussing treatment information, we did not explicitly ask patients whether or not they were able to understand what was being spoken in the other language. Lastly, inter-rater agreement could not be calculated as coding was done together by the two coders instead of separately. The strength of this study is that it adds to the sparse literature quantifying oncologists' encouragement of patient participation in decision making and providing prognostic information in an Asian setting.
In conclusion, this study shows that as recommended, Singaporean oncologists almost always listed more than one treatment option in most consultations. They also displayed other behaviours that encourage patient involvement. They potentially could do these at a higher level with some training. We hope to use these findings to develop interventions for both oncologists and patients to promote provision of information by oncologists and encourage effective patient participation and autonomy in decision making.
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